DENVER--(BUSINESS WIRE)--Myogen, Inc. (Nasdaq: MYOG), a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of cardiovascular disorders, today announced that an abstract describing the effects of darusentan on resistant hypertension (RHTN) has been selected for presentation at the International Society of Hypertension (ISH) to be held Oct. 15-19, 2006, in Fukuoka, Japan.
